Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 14, 2018 - Issue 4
Submit an article Journal homepage
694
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Lenvatinib-induced renal failure: two first-time case reports and review of literature

Stefano CavalieriHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyView further author information
,
Laura CosmaiNephrology Unit, ASST Santi Paolo e Carlo, Milan, ItalyView further author information
,
Augusto GenderiniNephrology Unit, ASST Fatebenefratelli – Luigi Sacco, Milan, ItalyView further author information
,
Manuela NebuloniPathology Unit, ASST Fatebenefratelli – Luigi Sacco, Milan, ItalyView further author information
,
Antonella TosoniPathology Unit, ASST Fatebenefratelli – Luigi Sacco, Milan, ItalyView further author information
,
Federica FavalesHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyView further author information
,
Paola PistilloHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyView further author information
,
Cristiana BergaminiHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyView further author information
,
Paolo BossiHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyView further author information
,
Lisa LicitraHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy;Department of Oncology, University of Milan, Milan, ItalyView further author information
,
Laura D. LocatiHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyView further author information
&
Salvatore AlfieriHead and Neck Cancer Medical Oncology 3 Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ItalyCorrespondence[email protected]
View further author information
 show all
Pages 379-385 | Received 15 Dec 2017, Accepted 03 Apr 2018, Published online: 13 Apr 2018

References

  • Yamamoto Y, Matsui J, Matsushima T, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.
  • Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372:621–630.
  • Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015 Nov;16:1473–1482.
  • Cheng AL, Finn RS, Qin S, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;35.
  • Vergote I, Teneriello M, Powell MA, et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol. 2013;31:5520.
  • Makker V, Rasco DW, Ductus CE, et al. A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma. J Clin Oncol. 2017;35:5598.
  • Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25.
  • Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas of the salivary glands: ACC-LEN14 (ACC-LEN14) - NCT02860936. [cited 2017 Dec 15]. Available from: https://clinicaltrials.gov/ct2/show/NCT02860936
  • Agenzia Italiana del Farmaco. [cited 2017 Dec 13]. Available from: http://www.agenziafarmaco.gov.it/
  • Porta C, Levy A, Hawkins R, et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014;3:1517–1526.
  • Brose MS, Worden FP, Newbold KL, et al. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J Clin Oncol. 2017 Aug 10;35(23):2692–2699. PubMed PMID: 28613956; eng.
  • Ikeda K, Kudo M, Kawazoe S, et al. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma. J Gastroenterol. 2017;52:512–519.
  • Kiyota N, Schlumberger M, Muro K, et al. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015;106:1714–1721.
  • Boissier E, Mir O, Hollebecque A, et al. Predictive factors of renal toxicities related to anti-VEGFR multikinase inhibitors in phase 1 trials. Invest New Drugs. 2017;35:79–86.
  • Cosmai L, Gallieni M, Liguigli W, et al. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephrol. 2017 Apr;30:171–180.
  • Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008 Mar 13;358:1129–1136.
  • Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn. 2010;37:347–363.
  • Smith ER, Tan SJ, Holt SG, et al. FGF23 is synthesised locally by renal tubules and activates injury-primed fibroblasts. Sci Rep. 2017 Jun 13;7:3345.
  • Lameire N. Nephrotoxicity of recent anti-cancer agents. Clin Kidney J. 2014 Feb;7:11–22.
  • Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015 May;87:909–917.
  • Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011 Dec;80:1271–1277.
  • Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37:2768–2801.
  • Porta C, Cosmai L, Gallieni M, et al. Renal effects of targeted anticancer therapies. Nat Reviews Nephrol. 2015;11:354–370.
  • Brandes AA, Bartolotti M, Tosoni A, et al. Practical Management of Bevacizumab-Related Toxicities in Glioblastoma. Oncologist. 2015;20:166–175.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.